{"id":"cycle-4-consolidation","_chembl":null,"_dailymed":null,"_scrapedAt":"2026-03-28T03:30:16.626Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123813,"model":"claude-sonnet-4-5-20250929"},"description":"Cycle 4 Consolidation is an investigational treatment regimen being studied by Gruppo Italiano Malattie EMatologiche dell'Adulto in Phase 2 clinical trials. As a consolidation therapy cycle, it is likely designed to maintain or deepen treatment response in hematologic malignancies following initial therapy.","indications":{"approved":[{"status":"investigational","condition":"Hematologic malignancy","patientPopulation":"Adult patients in consolidation phase"}]},"trialDetails":[{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma","enrollment":692},{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":100},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT06917911","phase":"PHASE2","title":"Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-18","conditions":"Core Binding Factor Acute Myeloid Leukemia","enrollment":162},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT01386385","phase":"PHASE1, PHASE2","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma","enrollment":53},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT06313437","phase":"PHASE1","title":"Revumenib in Combination With 7+3 + Midostaurin in AML","status":"RECRUITING","sponsor":"Richard Stone, MD","startDate":"2024-12-06","conditions":"Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations","enrollment":22},{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":"Acute Myeloid Leukemia","enrollment":273},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT02971397","phase":"PHASE1","title":"Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-11","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT05690984","phase":"PHASE2","title":"Elimination of Minimal Residual Disease After Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-06-26","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT06138275","phase":"PHASE2","title":"Elranatamab in R/R Multiple Myeloma","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-03-08","conditions":"Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma","enrollment":32},{"nctId":"NCT03591510","phase":"PHASE2","title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-13","conditions":"FLT3-mutated Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT06577025","phase":"PHASE2","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-20","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT03477539","phase":"PHASE2","title":"Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-04-09","conditions":"Plasma Cell Myeloma","enrollment":49},{"nctId":"NCT04231851","phase":"PHASE2","title":"CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Irvine","startDate":"2020-02-19","conditions":"Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes","enrollment":30},{"nctId":"NCT07060001","phase":"PHASE2","title":"Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)","enrollment":112},{"nctId":"NCT02835222","phase":"PHASE2","title":"Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-02-02","conditions":"Untreated Adult Acute Myeloid Leukemia","enrollment":57},{"nctId":"NCT05502250","phase":"PHASE2","title":"Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2023-07-14","conditions":"Hodgkin Lymphoma","enrollment":75},{"nctId":"NCT05306301","phase":"PHASE2","title":"Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2022-10-05","conditions":"Chemotherapy, Leukemia, Acute Lymphoblastic","enrollment":32},{"nctId":"NCT03214562","phase":"PHASE1, PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":"High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT07451912","phase":"PHASE1, PHASE2","title":"Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-15","conditions":"Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML","enrollment":29},{"nctId":"NCT04802356","phase":"PHASE2","title":"Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2021-04-07","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04716946","phase":"PHASE2","title":"Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-27","conditions":"NSCLC, Non-small Cell Lung Cancer, Lung Cancer","enrollment":13},{"nctId":"NCT07223190","phase":"PHASE3","title":"A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia","status":"NOT_YET_RECRUITING","sponsor":"Amgen","startDate":"2026-06-11","conditions":"Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia","enrollment":560},{"nctId":"NCT06719700","phase":"PHASE2","title":"Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Toripalimab, Surufatinib, Chemoradiotherapy","enrollment":47},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT05870917","phase":"PHASE2","title":"A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-04-25","conditions":"Plasma Cell Leukemia","enrollment":20},{"nctId":"NCT07039162","phase":"PHASE2","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Ming-Yu Lien","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer","enrollment":45},{"nctId":"NCT06773910","phase":"PHASE2","title":"BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-03-11","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":250},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT05650723","phase":"PHASE2","title":"Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":50},{"nctId":"NCT03609593","phase":"PHASE2","title":"Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Nicole Lamanna","startDate":"2018-11-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":42},{"nctId":"NCT07425795","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-10","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":36},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT03629171","phase":"PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-29","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":52},{"nctId":"NCT04915612","phase":"PHASE1","title":"Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-21","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT04892953","phase":"PHASE2","title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-07","conditions":"Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8","enrollment":51},{"nctId":"NCT05579132","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","status":"RECRUITING","sponsor":"MSD R&D (China) Co., Ltd.","startDate":"2022-11-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":203},{"nctId":"NCT05673772","phase":"PHASE2","title":"Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":"Rectal Cancer","enrollment":364},{"nctId":"NCT02875314","phase":"PHASE4","title":"HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parth Patel","startDate":"2015-09","conditions":"Medulloblastoma, Central Nervous System Embryonal Tumors","enrollment":250},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT03710603","phase":"PHASE3","title":"Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2018-12-14","conditions":"Multiple Myeloma","enrollment":709},{"nctId":"NCT01358747","phase":"PHASE3","title":"Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2011-05","conditions":"Hodgkin's Lymphoma","enrollment":""},{"nctId":"NCT01515527","phase":"PHASE2","title":"Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-07","conditions":"Leukemia","enrollment":160},{"nctId":"NCT06580301","phase":"PHASE1, PHASE2","title":"Study of YK012 in B-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Excyte Biopharma Ltd","startDate":"2024-09-25","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":46},{"nctId":"NCT02525757","phase":"PHASE2","title":"MPDL3280A With Chemoradiation for Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-26","conditions":"Lung Cancer, Non-Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT07381777","phase":"PHASE2","title":"XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2026-01-31","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":270},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05016947","phase":"PHASE1","title":"Venetoclax Plus Inotuzumab for B-ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-09-24","conditions":"B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL","enrollment":23},{"nctId":"NCT05925530","phase":"PHASE2","title":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-22","conditions":"Non-small Cell Lung Cancer","enrollment":142},{"nctId":"NCT07375563","phase":"PHASE3","title":"Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-11-19","conditions":"Neuroblastoma (NB), Ganglioneuroblastoma","enrollment":5},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":"Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":13},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT01231906","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2010-11-24","conditions":"Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues","enrollment":642},{"nctId":"NCT06974786","phase":"PHASE2","title":"Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-08-08","conditions":"Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)","enrollment":100},{"nctId":"NCT07358676","phase":"PHASE2","title":"A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage","enrollment":25},{"nctId":"NCT06769126","phase":"PHASE2","title":"Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-11-06","conditions":"Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype","enrollment":900},{"nctId":"NCT07228273","phase":"PHASE2","title":"Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-12","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":102},{"nctId":"NCT03701308","phase":"PHASE2, PHASE3","title":"Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-28","conditions":"Acute Myeloid Leukemia","enrollment":267},{"nctId":"NCT03285321","phase":"PHASE2","title":"Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Greg Durm, MD","startDate":"2017-09-15","conditions":"Non-small Cell Lung Cancer","enrollment":105},{"nctId":"NCT03709758","phase":"PHASE1","title":"Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-10-17","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT07340489","phase":"PHASE2","title":"Serplulimab for Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-03","conditions":"Cervical Cancer","enrollment":216},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT06776991","phase":"NA","title":"Reward Processing and Exposure Therapy for Social Anxiety Disorder","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2024-09-26","conditions":"Social Anxiety Disorder (Social Phobia), Public Speaking Anxiety, Anhedonia","enrollment":94},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07321912","phase":"PHASE2","title":"Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-04-01","conditions":"Osteosarcoma, Ewing Sarcoma, Ewing Sarcoma Metastatic","enrollment":406},{"nctId":"NCT07326371","phase":"PHASE2","title":"Glofitamab Combined With CAR-T Therapy in R/R DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":24},{"nctId":"NCT05464329","phase":"PHASE1","title":"Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-03","conditions":"Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma","enrollment":24},{"nctId":"NCT05327894","phase":"PHASE3","title":"Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2022-12-15","conditions":"Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":160},{"nctId":"NCT07108998","phase":"PHASE2","title":"Study of Epcoritamab as a Consolidation Therapy in CLL/SLL","status":"RECRUITING","sponsor":"Zulfa Omer","startDate":"2025-08-22","conditions":"CLL/SLL, CLL, SLL","enrollment":22},{"nctId":"NCT01208766","phase":"PHASE3","title":"Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2011-01","conditions":"Multiple Myeloma","enrollment":1503},{"nctId":"NCT05249959","phase":"PHASE2","title":"Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2022-03-21","conditions":"Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":49},{"nctId":"NCT07281157","phase":"PHASE2","title":"Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-11-01","conditions":"Advanced Colorectal Cancer","enrollment":30},{"nctId":"NCT07296445","phase":"PHASE3","title":"A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)","status":"NOT_YET_RECRUITING","sponsor":"SDK Therapeutics, Inc.","startDate":"2026-01","conditions":"Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA","enrollment":120},{"nctId":"NCT07306663","phase":"PHASE3","title":"Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2021-06-01","conditions":"Esophageal Cancer","enrollment":242},{"nctId":"NCT03410043","phase":"PHASE2","title":"Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-01-17","conditions":"Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8","enrollment":173},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":"Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma","enrollment":537},{"nctId":"NCT04802161","phase":"PHASE2","title":"Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-24","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia","enrollment":50},{"nctId":"NCT04659616","phase":"PHASE1","title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-01-14","conditions":"Acute Myeloid Leukemia","enrollment":32},{"nctId":"NCT05801939","phase":"PHASE2","title":"Cevostamab Following CAR T Cell Therapy for RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-07-11","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT07291401","phase":"PHASE2","title":"Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","status":"NOT_YET_RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2026-01-01","conditions":"Rectal Cancer Patients","enrollment":108},{"nctId":"NCT07291102","phase":"PHASE3","title":"Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2026-07-01","conditions":"Medulloblastoma","enrollment":96},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT04128748","phase":"PHASE1, PHASE2","title":"Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-27","conditions":"Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome","enrollment":52},{"nctId":"NCT04047641","phase":"PHASE1, PHASE2","title":"Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-22","conditions":"Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VCR + IDR + CY + ARA-C + 6-MP + DXM + IT"],"phase":"phase_2","status":"active","brandName":"Cycle 4 Consolidation","genericName":"Cycle 4 Consolidation","companyName":"Gruppo Italiano Malattie EMatologiche dell'Adulto","companyId":"gruppo-italiano-malattie-ematologiche-dell-adulto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cycle 4 Consolidation is a treatment protocol for certain types of Acute Myeloid Leukemia, involving the use of Cytarabine, Daunorubicin Hydrochloride, and possibly Dasatinib. This treatment is specifically designed for patients with Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, and Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1.","enrichmentLevel":2,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}